CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 100 enrolled
Drug / intervention
Rolipram +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00369798
NCT00369798Phase 1Completed
CompareCT.gov

Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE 4) in Depressed Patients

National Institute of Mental Health (NIMH)·interventional·Posted Aug 29, 2006·Updated Jul 5, 2018

In Brief

A Phase 1 clinical trial evaluating PET scan and Rolipram for Major Depressive Disorder and Healthy. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The primary purpose of this protocol is to compare PDE4 levels before and after starting a selective serotonin reuptake inhibitor (SSRI) sertraline, citalopram or escitalopram in unmedicated depressed patients. The secondary purpose is to compare PDE4 levels between unmedicated depressed patients and healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder, Healthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 29, 2006
Enrollment StartAug 2, 2006
Primary CompletionJun 16, 2016
Study CompletionOct 12, 2016
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 19.8 years ago

Interventions

PET scanprocedure

Rolipramdrug